Mixed Chimeric Transplantation for Primary Amyloidosis

This study has been withdrawn prior to recruitment.

Sponsored by:	Stanford University
Information provided by:	Stanford University
ClinicalTrials.gov Identifier:	NCT00186095

Purpose

To evaluate the role of nonmyeloablative allogeneic transplantation in Amyloidosis.

Condition	Intervention
Amyloidosis	Procedure: autologous followed by nonmyeloablative allogeneic transplant

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment
Official Title:	Mixed Chimeric Transplantation for Primary Amyloidosis

Further study details as provided by Stanford University:

Primary Outcome Measures:

Treatment of patients with nonmyeloablative allogeneic transplant for amyloidosis.

Secondary Outcome Measures:

Estimated Enrollment:	45
Study Start Date:	December 2000
Estimated Study Completion Date:	September 2006

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00186095

Sponsors and Collaborators

Stanford University

Investigators

Principal Investigator:

Keith Stockerl-Goldstein, MD

Stanford University

More Information

Study ID Numbers:	BMT129
Study First Received:	September 13, 2005
Last Updated:	October 5, 2007
ClinicalTrials.gov Identifier:	NCT00186095
Health Authority:	United States: Institutional Review Board

Keywords provided by Stanford University:

Amyloidosis
nonmyeloablative
hematopoietic
cell transplantation

Study placed in the following topic categories:

Amyloidosis
Metabolic Diseases
Primary Amyloidosis
Metabolic disorder

ClinicalTrials.gov processed this record on January 15, 2009